Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells

Cancer Science

Volumn 97, Issue 11, 2006, Pages 1198-1204

  Mutoh, Kazuyoshi ^a   Tsukahara, Satomi ^b   Mitsuhashi, Junko ^a,b   Katayama, Kazuhiro ^a   Sugimoto, Yoshikazu ^a  

^a KEIO UNIVERSITY   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; DIETHYLSTILBESTROL; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTRONE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PROGESTERONE; TAMOXIFEN; VINCRISTINE;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; DRUG PROTEIN BINDING; DRUG SENSITIVITY; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAMOXIFEN; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 33748930643     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00300.x     Document Type: Article

References (41)

1. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985; 316: 817-19.
2. Chen CJ, Chin JE, Ueda K et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-9.
3. Shen DW, Fojo A, Chin JE et al. Human multidrug-resistant cell lines: increased MDR1 expression can precede gene amplification. Science 1986; 232: 643-5.
4. Gottesman MM, Hrycyna CA, Schoenlein PV, Germamm UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995; 29: 607-49.
5. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of full-length cDNA for the human 'MDR1 'gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987; 84: 3004-8.
6. Pirker R, Wallnar J, Geissler K et al. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708-12.
7. Goldstein LJ, Galski H, Fojo A et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24.
8. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-72.
9. Chambers SK, Hait WN, Kacinski BM, Keyes SR, Handschumacher RE. Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporine A and its analogues. Cancer Res 1989; 49: 6275-9.
10. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-9.
11. Cordon-Cardo C, O'Brien JP, Casals D et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695-8.
12. Wilson WH, Jamis-Dow C, Bryant G et al. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J Clin Oncol 1995; 13: 1985-94.
13. Lum BL, Kaubisch S, Yahanda AM et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-42.
14. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Estrone and 17β-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 2002; 93: 231-5.
15. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2003; 2: 105-12.
16. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 2003; 278: 22644-9.
17. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 2003; 64: 610-8.
18. Imai Y, Ishikawa E, Asada S, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ ABCG2. Cancer Res 2005; 65: 596-604.
19. Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J. Breast cancer resistance protein: Molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci 2005; 96: 457-65.
20. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985; 316: 820-3.
21. Okochi E, Iwahashi T, Ariyoshi K, Watabe H, Tsuruo T, Ono K. Establishment and evaluation of MRK16-magnetic cell sorting assays for detecting low expression of multidrug resistance P-glycoprotein using human leukemia cell lines and peripheral blood cells from healthy donors. J Immunol Meth 1995; 187: 127-37.
22. Pirnia F, Breuleux M, Schneider E et al. Uncertain Identity of Doxorubicin-Resistant MCF-7 Cell Lines Expressing Mutated p53. J Natl Cancer Inst 2000; 92: 1535-6.
23. Sugimoto Y, Aksentijevich I, Gottesman MM, Pastan I. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. Biotechnology 1994; 12: 694-8.
24. Zhang S, Sugimoto Y, Shoshani T, Pastan I, Gottesman MM. A pHaMDR-DHFR bicistronic expression system for mutation analysis of P-glycoprotein. Meth Enzymol 1998; 292: 474-80.
25. Sugimoto Y, Tsukahara S, Sato S et al. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1 -bicistronic retrovirus vector Ha-MDR-IRES-gp91. J Gene Med 2003; 5: 366-76.
26. Kessel D, Beck WT, Kukuruga D, Schulz V. Characterization of multidrug resistance by fluorescent dyes. Cancer Res 1991; 51: 4665-70.
27. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Over expression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-9.
28. Arceci RJ, Croop JM, Horwitz SB, Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988; 85: 4350-4.
29. Arceci RJ, Baas F, Raponi R, Horwitz SB, Housman D, Croop JM. Multidrug resistance gene expression is controlled by steroid hormones in the secretory epithelium of the uterus. Mol Reprod Dev 1990; 25: 101-9.
30. Gil S, Saura R, Forestier F, Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta 2005; 26: 268-70.
31. Tolcher AW, Cowan KH, Solomon D et al. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1173-84.
32. Lehnert M, Mross K, Schuller J, Thuerlimann B, Kroeger N, Kupper H. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Br J Cancer 1998; 77: 1155-63.
33. Warner E, Hedley D, Andrulis I et al. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin Cancer Res 1998; 4: 1451-7.
34. Toppmeyer D, Seidman AD, Pollak M et al. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res 2002; 8: 670-8.
35. Tidefelt U, Liliemark J, Gruber A et al. P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia. J Clin Oncol 2000; 18: 1837-44.
36. Ramu A, Glaubiger D, Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 1984; 44: 4392-5.
37. Millward MJ, Cantwell BM, Lien EA, Carmichael J, Harris AL. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992; 28A: 805-10.
38. Stuart NS, Philip P, Harris AL et al. High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 1992; 66: 833-9.
39. Trump DL, Smith DC, Ellis PG et al. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 1992; 84: 1811-16.
40. Weinlander G, Kornek G, Raderer M, Hejna M, Tetzner C, Scheithauar W. Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: High-dose oral tamoxifen and dexverapamil. J Cancer Res Clin Oncol 1997; 123: 452-5.
41. Samuels BL, Hollis DR, Rosner GL et al. Modulation of vincristine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: A cancer and leukemia group B study. Clin Cancer Res 1997; 3: 1977-84.